CorreGene completed series Pre-A financing of nearly 100 million yuans

Recently, Beijing CorreGene Biotechnology Co., Ltd. (hereinafter referred to as "CorreGene") announced the completion of nearly 100 million yuan of pre-A financing. This round of financing was led by CD Capital, followed by Chantou Capital、Riverhead Capital、Beijing Changping Science Park Development Co., Ltd and other institutions, the old shareholder Anlong Capital added investment and continued support. The funds will be invested to develop the company's multiple clinical pipelines, including TCR-T cell therapeutic products for HPV positive cervical cancer and head and neck tumors, the first cell therapy product targeting KRAS-G12 mutation colorectal cancer and pancreatic cancer, and related TCR-fusion protein therapy.

CorreGene is a clinical-stage biotechnology committed to the development of innovative therapies based on T cell receptor (TCR), has established a comprehensive research and development platform for T cell receptor (TCR) technology, incorporating breakthroughs in TCR cloning and affinity optimization. In particular, the proprietary SMART-TCR affinity optimization platform, a revolutionary technology in TCR affinity optimization, has significantly increased the success rate and efficiency of TCR optimization. This groundbreaking platform has effectively overcome previous barriers in the development of TCR-based medications.

Currently, CorreGene is developing multiple First-in-class TCR-T cell therapies and TCR bispecifics, including the pioneering cell therapy drug targeting the KRAS-G12 mutations in China and world-first TCR bispecific targeting HPV infectious diseases, aiming to building a global leader in TCR-based immunotherapies.

In the future, CorreGene will pioneering distinct therapeutic modalities of T cell receptors (TCRs) for ACT and Bispecifics for tumor, chronic infection and autoimmune disease, aiming to the trillion-level markets.